62522-63-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Benzoxazolesulfonylchloride,2,3-dihydro-3-methyl-2-oxo-(9CI) is used as a building block for the synthesis of various drugs and pharmaceutical products. Its role in this industry is crucial for the development of new medications and the improvement of existing ones.
Used in Specialty Chemicals Production:
In the specialty chemicals sector, 6-Benzoxazolesulfonylchloride,2,3-dihydro-3-methyl-2-oxo-(9CI) is employed as a key intermediate in the manufacturing process. Its unique properties allow for the creation of a variety of specialty chemicals with specific applications.
Used in Agrochemicals Manufacturing:
6-Benzoxazolesulfonylchloride,2,3-dihydro-3-methyl-2-oxo-(9CI) also finds application in the agrochemicals industry, where it is used in the synthesis of compounds that contribute to agricultural advancements, such as pesticides and fertilizers.
Used in Chemical Research and Development:
As a significant intermediate in the production of a wide range of organic compounds, 6-Benzoxazolesulfonylchloride,2,3-dihydro-3-methyl-2-oxo-(9CI) is instrumental in chemical research and development. It aids scientists in exploring new chemical reactions and discovering innovative applications for existing compounds.

Upstream product

• 1216666-32-8 3-methyl-2-oxobenzoxazolin-6-ylsulfonic acid 
• 59-49-4 2-Benzoxazolinone 
• 21892-80-8 3-methylbenzo[d]oxazol-2(3H)-one 

Downstream Products

• 1393726-94-7 6-(4-(4-acetylphenyl)piperazin-1-ylsulfonyl)-3-methylbenzo[d]oxazol-2(3H)-one 
• 901752-69-0 N-(3,4-dimethylphenyl)-3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 
• 62522-62-7 3-methylbenzoxazolone-6-sulfonamide 

Relevant academic research and scientific papers

Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity

Botulinum neurotoxins (BoNT) are among the most poisonous substances known, and of the 7 serotypes (A–G) identified thus far at least 4 can cause death in humans. The goal of this work was identification of inhibitors that specifically target the light ch

N-acyl sulfamide FBPase inhibitor, preparation method thereof, drug composition and application

The invention discloses an N-acryl sulfamide FBPase inhibitor of a novel structure, and a preparation method thereof, a drug composition and an application, and particularly relates to an N-acryl sulfamide FBPase inhibitor shown in the formula I, a salt thereof for medicine, a preparation method, a composition comprising one or more compounds, an application of the compound in preparing the FBPase inhibitor or a drug for treating FBPase-related diseases, and an application in preparing a drug for preventing and/or treating diabetes. The formula is shown in the description.

Benzazoles. 4.* Synthesis and chemical reactions of 6-chlorosulfonylbenzoxazolin-2-ones

The corresponding 6-chlorosulfonyl derivatives were synthesized from benzoxazolin-2-one and its 3-methyl derivative by treatment with chlorosulfonic acid. By treatment of the compounds obtained with water and other nucleophilic reagents (aliphatic and heterocyclic amines) 2-oxobenzoxazoline-6-sulfonic acids and a series of their amides were obtained, while reduction with SnCl 2?2H2O gave 6-mercaptobenzoxazolin-2-ones.

ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, A, B, D, E, G, Ar, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5HT6 receptor which are of the formula (I), wherein R1-R3 A, B, D, E, G, Q, and x are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.